Atopix appoints Andrew Zambanini as chief medical officer

UK biotech company Atopix Therapeutics has appointed Andrew Zambanini as chief medical officer.

He joins Atopix as it advances the clinical development of its lead CRTH2 antagonist, OC459, in multiple indications. Dr Zambanini brings almost 25 years of experience in clinical medicine and pharmaceuticals, including GlaxoSmithKline (LSE: GSK).

Tim Edwards, executive chairman of Atopix, said: “I’m pleased to welcome Andy to Atopix.  We recently received approval to begin a Phase IIa study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, and trials are also continuing in atopic dermatitis and moderate, steroid-free, eosinophilic asthma. Andrew’s breadth of knowledge and his experience of developing and managing clinical trials will be invaluable to the Company as we seek to realize the potential of OC459 and ATX2417.”